Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells

被引:55
作者
Hendriks, BS
Orr, G
Wells, A
Wiley, HS
Lauffenburger, DA [1 ]
机构
[1] MIT, Dept Chem Engn, Cambridge, MA 02139 USA
[2] MIT, Dept Biol, Biol Engn Div, Cambridge, MA 02139 USA
[3] MIT, Canc Res Ctr, Cambridge, MA 02139 USA
[4] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA
[5] Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA
关键词
D O I
10.1074/jbc.M410491200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HER2, a member of the epidermal growth factor receptor (EGFR) tyrosine kinase family, functions as an accessory EGFR signaling component and alters EGFR trafficking by heterodimerization. HER2 overexpression leads to aberrant cell behavior including enhanced proliferation and motility. Here we applied a combination of computational modeling and quantitative experimental studies of the dynamic interactions between EGFR and HER2 and their downstream activation of ERK to understand this complex signaling system. Using cells expressing different levels of HER2 relative to the EGFR, we could separate relative contributions of EGFR and HER2 to signaling amplitude and duration. Based on our model calculations, we demonstrated that, in contrast with previous suggestions in the literature, the intrinsic capabilities of EGFR and HER2 to activate ERK were quantitatively equivalent. We found that HER2-mediated effects on EGFR dimerization and trafficking were sufficient to explain the observed HER2-mediated amplification of epidermal growth factor-induced ERK signaling. Our model suggests that transient amplification of ERK activity by HER2 arises predominantly from the 2-to-1 stoichiometry of receptor kinase to bound ligand in EGFR/HER2 heterodimers compared with the 1-to-1 stoichiometry of the EGFR homodimer, but alterations in receptor trafficking yielding increased EGFR sparing cause the sustained HER2-mediated enhancement of ERK signaling.
引用
收藏
页码:6157 / 6169
页数:13
相关论文
共 41 条
[1]   Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].
Agus, DB ;
Akita, RW ;
Fox, WD ;
Lewis, GD ;
Higgins, B ;
Pisacane, PI ;
Lofgren, JA ;
Tindell, C ;
Evans, DP ;
Maiese, K ;
Scher, HI ;
Sliwkowski, MX .
CANCER CELL, 2002, 2 (02) :127-137
[2]   The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions [J].
Alroy, I ;
Yarden, Y .
FEBS LETTERS, 1997, 410 (01) :83-86
[3]   Quantitative relationship among integrin-ligand binding, adhesion, and signaling via focal adhesion kinase and extracellular signal-regulated kinase 2 [J].
Asthagiri, AR ;
Nelson, CM ;
Horwitz, AF ;
Lauffenburger, DA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (38) :27119-27127
[4]   A computational study of feedback effects on signal dynamics in a mitogen-activated protein kinase (MAPK) pathway model [J].
Asthagiri, AR ;
Lauffenburger, DA .
BIOTECHNOLOGY PROGRESS, 2001, 17 (02) :227-239
[5]   A rapid and sensitive quantitative kinase activity assay using a convenient 96-well format [J].
Asthagiri, AR ;
Horwitz, AF ;
Lauffenburger, DA .
ANALYTICAL BIOCHEMISTRY, 1999, 269 (02) :342-347
[6]   DISTINCTIVE TRAITS OF NORMAL AND TUMOR-DERIVED HUMAN MAMMARY EPITHELIAL-CELLS EXPRESSED IN A MEDIUM THAT SUPPORTS LONG-TERM GROWTH OF BOTH CELL-TYPES [J].
BAND, V ;
SAGER, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (04) :1249-1253
[7]   Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking [J].
Burke, P ;
Schooler, K ;
Wiley, HS .
MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (06) :1897-1910
[8]  
Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO
[9]  
2-T
[10]   HETERODIMERIZATION AND FUNCTIONAL INTERACTION BETWEEN EGF RECEPTOR FAMILY MEMBERS - A NEW SIGNALING PARADIGM WITH IMPLICATIONS FOR BREAST-CANCER RESEARCH [J].
EARP, HS ;
DAWSON, TL ;
LI, X ;
YU, H .
BREAST CANCER RESEARCH AND TREATMENT, 1995, 35 (01) :115-132